We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.50
Bid: 55.50
Ask: 57.50
Change: 0.00 (0.00%)
Spread: 2.00 (3.604%)
Open: 56.50
High: 56.50
Low: 56.50
Prev. Close: 56.50
BSC Live PriceLast checked at -
British Smaller Companies VCT 2 is an Investment Trust

To create a portfolio that blends a mix of businesses operating in established industries with those that offer opportunities in the application and development of innovation.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

24 Jun 2020 11:15

RNS Number : 9414Q
British Smaller Companies VCT2 Plc
24 June 2020
 

British Smaller Companies VCT2 plc

Interim Management Statement

For the quarter ended 31 March 2020

British Smaller Companies VCT2 plc (the "Company") presents its interim management statement for the quarter ended 31 March 2020. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

The Company's Total Return at 31 March 2020 was 114.9 pence per ordinary share, representing an increase of 0.3 pence per ordinary share over the Total Return of 114.6 pence per ordinary share announced on 25 March 2020.

As previously reported, on 10 March 2020 the Company realised its investment in Business Collaborator Limited for £5.1 million, compared to a valuation of £3.5 million at 31 December 2019. The realised gain of £1.6 million has been included in the Total Return announced today.

Performance

The movement in Total Return in pence per ordinary share is set out in the table below:

Pence per

ordinary share

Cumulative dividends to 31 December 2019

66.5

Net Asset Value ("NAV") at 31 December 2019

55.2

Total Return at 31 December 2019

121.7

Net underlying movement in portfolio

(6.5)

Net result after expenses / share buy-backs

(0.3)

Decrease in Total Return

(6.8)

Total Return at 31 March 2020

114.9

 

31 March 2020

Movement

31 December 2019

Net Assets (£m)

62.8

(9.5)

72.3

NAV per share (PPS)

48.4p

(6.8p)

55.2p

Cumulative dividends paid (PPS)

66.5p

-

66.5p

Total Return (PPS)

114.9p

(6.8p)

121.7p

Shares in issue

129,883,515

(1,217,031)

131,100,546

 

The Total Return at 31 March 2020, calculated by reference to the NAV per ordinary share and the cumulative dividends paid per ordinary share, was 114.9 pence per ordinary share compared to 121.7 pence per ordinary share at 31 December 2019.

The unaudited NAV per ordinary share as at 31 March 2020 was 48.4 pence per ordinary share (31 December 2019: 55.2 pence per ordinary share) representing a decrease of 6.8 pence per ordinary share from the portfolio/net income.

Cumulative dividends paid were unchanged at 66.5 pence per ordinary share (31 December 2019: 66.5 pence per ordinary share).

The movement in NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 31 December 2019

72.3

55.2

Net underlying movement in portfolio

(8.5)

(6.5)

Net income after expenses

(0.4)

(0.3)

Shares buybacks

(0.6)

-

Increase

(9.5)

(6.8)

NAV at 31 March 2020

62.8

48.4

Dividends and shares in issue

On 2o March 2020 the Company purchased 1,217,031 ordinary shares of 10 pence each at a price of 52.44 pence per ordinary share. These shares were placed in treasury.

The number of ordinary shares in issue at 31 March 2020 was 129,883,515 (31 December 2019: 131,100,546). In addition, at 31 March 2020 the Company held 10,526,123 ordinary shares in treasury (31 December 2019: 9,309,092).

An interim dividend of 2.0 pence per ordinary share was paid on 12 May 2020, taking cumulative dividends paid at that date to 68.5 pence per ordinary share.

Dividend Reinvestment Scheme (DRIS) and share buybacks

The DRIS and buyback schemes were suspended in March due to the severe market disruption. Since then there has been more clarity over how the restrictions imposed in managing the coronavirus and the various Government measures of support have been applied. As a result, whilst there may still be caution over the general economic conditions, this has resulted in some recovery and stability. As a result the Directors have decided to reinstate the Company's DRIS and buyback schemes as of the date of this announcement.

Net assets

Net assets at 31 March 2020 comprised the following:

£000

% of net assets

Unquoted investments

34,681

55.2%

Cash and cash equivalents

27,777

44.2%

Other net current assets

356

0.6%

Net assets

62,814

100%

 

The investment portfolio at 31 March 2020 comprised:

Valuation

£000

Valuation as a % of net assets

Matillion Limited

6,295

10.0%

ACC Aviation Group Limited

5,014

8.0%

Intelligent Office UK

2,711

4.3%

KeTech Enterprises Limited

2,197

3.5%

Unbiased EC1 Limited

2,022

3.2%

Elucidat Ltd

1,432

2.3%

Wooshii Limited

1,377

2.2%

Deep-Secure Ltd

1,300

2.1%

Springboard Research Holdings Limited

1,251

2.0%

Arcus Global Limited

1,108

1.7%

24,707

39.3%

Other investments

9,974

15.9%

Total investments

34,681

55.2%

 

There were 3 follow-on investments totalling £0.3 million during the quarter.

In the quarter to 31 March 2020 the realisation and repayment of investments generated cash proceeds of £5.1 million.

Investments made prior to the November 2015 Budget represented 45 per cent of the value of the unquoted portfolio at 31 March 2020.

Portfolio performance

Over the quarter to 31 March 2020 the aggregate unrealised portfolio valuation has decreased by £10.1 million as a result of the impact of the coronavirus pandemic on public markets. The Board continues to follow its policy of maintaining a diversified portfolio. At 31 March 2020, only two investments represented more than 5 per cent of the Company's NAV, the largest being 10.0 per cent, with the top ten investments representing 39.3 per cent of NAV (31 December 2019 42.5 per cent).

Board composition

The Board is currently recruiting a replacement for Robert Pettigrew, a long serving director, who intends to stand down later this year. The Board believe that new directors with new approaches, balanced with a level of continuity, are good for decision making within the Board.

Outlook

The coronavirus pandemic has caused a massive shock to the global economy with activity curtailed and a lockdown imposed. The Company is well funded and well placed to support its portfolio of investments, albeit to date only there has been a small need for additional funding. There continues to be demand for growth capital and there is every likelihood this could increase as the Government's intervention measures are withdrawn and again the Company is ideally placed to provide support and to take advantage of new opportunities.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

24 June 2020

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFZGZVLDLGGZG
Date   Source Headline
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.